Core Viewpoint - Immutep Ltd. experienced a significant stock decline of approximately 80% to 90% following the recommendation from an Independent Data Monitoring Committee to halt the Phase III TACTI-004 trial due to an interim futility analysis indicating the drug was unlikely to meet efficacy endpoints [1][2]. Group 1: Company Performance - The TACTI-004 trial was Immutep's lead clinical-stage oncology program, and prior to the halt, the company had reported "strong operational progress" and indicated that the futility analysis was "on track for the first quarter of CY2026" in a filing dated January 30, 2026 [2]. - Following the announcement on March 13, 2026, the stock fell dramatically in a single session, reflecting investor reaction to the trial's discontinuation [2]. Group 2: Legal Investigation - Levi & Korsinsky is investigating whether Immutep failed to adequately disclose material information regarding the status and interim results of the TACTI-004 futility analysis prior to the March 13 announcement [3]. - Shareholders who incurred losses on their investments in Immutep are encouraged to submit their information as part of the investigation [3].

Core Viewpoint - Immutep Ltd. is facing a securities fraud lawsuit after allegedly misrepresenting the progress of its Phase III TACTI-004 trial, leading to significant losses for investors when the trial was halted due to failure to meet efficacy endpoints [1][2][3]. Group 1: Trial Progress and Misrepresentation - On January 30, 2026, Immutep reported that the futility analysis for the TACTI-004 trial was "on track" and described "strong operational progress" [2]. - Just six weeks later, on March 13, 2026, the Independent Data Monitoring Committee (IDMC) recommended halting the trial after determining it was unlikely to meet its primary efficacy endpoints [2][3]. - The lack of public disclosure regarding any changes in the trial's outlook between the January 30 filing and the March 13 announcement raised concerns among investors [3]. Group 2: Financial Impact - Following the IDMC's recommendation to halt the trial, Immutep's stock price collapsed by approximately 80-90% in a single session [1][3]. - The TACTI-004 trial was considered the company's lead oncology asset, making the impact of the trial's failure particularly significant for shareholders [3].

Core Viewpoint - Immutep Limited is under investigation for potential securities fraud following the discontinuation of its TACTI-004 Phase III study due to a recommendation from the Independent Data Monitoring Committee (IDMC) [1][3]. Group 1: Company Developments - On March 13, 2026, Immutep announced the IDMC's recommendation to discontinue the TACTI-004 Phase III study evaluating eftilagimod alfa in patients with 1st line non-small cell lung cancer after a planned interim futility analysis [3]. - The IDMC concluded that the trial should be halted based on the available safety and efficacy data, leading to an orderly wind down of the study, including patient follow-up and site closure [3]. - Following this announcement, Immutep's American Depositary Receipt (ADR) price fell by $2.27, or 82.44%, closing at $0.48 per ADR on March 13, 2026 [3]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Immutep investors regarding potential securities fraud or unlawful business practices by the company and its officers and/or directors [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2].

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Immutep Limited following a significant decline in stock price after the discontinuation of a clinical trial [1][3][4]. Group 1: Investigation Details - The investigation focuses on whether Immutep's executive officers may have violated federal securities laws, leading to investor losses [1][4]. - The Independent Data Monitoring Committee recommended discontinuation of Immutep's Phase III TACTI-004 clinical trial due to an interim futility analysis indicating the trial was unlikely to meet its primary endpoints [3]. Group 2: Stock Performance - Following the announcement of the trial discontinuation, Immutep's stock price plummeted approximately 85–90% in a single trading session [4]. Group 3: Legal Firm Background - Johnson Fistel, PLLP is a nationally recognized law firm specializing in shareholder rights and has recovered approximately $90,725,000 for clients in securities class action lawsuits [5][6].

Core Insights - Dr. Reddy's Laboratories Limited (RDY) reported Q3 fiscal 2026 earnings of 16 cents per American Depositary Share (ADS), matching the Zacks Consensus Estimate, but down from 19 cents per ADS in the same quarter last year [1][5] - Revenues increased by 4.4% year over year to $971 million, but fell short of the Zacks Consensus Estimate of $978 million, primarily due to lower growth in global generics revenues [1][5] Revenue Breakdown - Global Generics revenues reached INR 79.1 billion, reflecting a 7% year-over-year increase, driven by growth in key markets and favorable foreign exchange movements, although North America Generics saw a decline [2][5] - Pharmaceutical Services & Active Ingredients (PSAI) revenues totaled INR 8 billion, down 2% year over year due to lower volume uptake in the active pharmaceutical ingredient (API) business [6] - Revenues in the Others segment were INR 0.1 billion, a significant decline of 92% year over year [6] North America Performance - North America segment revenues decreased by 12% due to lower sales of lenalidomide and increased price erosion in key products [3][5] - As of December 31, 2025, there were 73 generic filings pending FDA approval, including 71 abbreviated new drug applications (ANDAs) and two new drug applications, with 43 of the ANDAs being Para IVs [3] Margin and Expenses - Gross margin fell by 505 basis points year over year to 53.6%, attributed to lower lenalidomide sales, price erosion, adverse product mix in PSAI, and one-time provisions related to new Labor Codes in India [7][5] - Research and development (R&D) expenses were $68 million, down 8% year over year, primarily due to reduced spending in biosimilars [8] - Selling, general and administrative expenses rose to $300 million, a 12% increase year over year, driven by investments in branded franchises and adverse foreign exchange movements [9] Strategic Developments - Dr. Reddy's gained approval for AVT03, a proposed biosimilar to Amgen's Prolia and Xgeva, in the EU and the UK, and launched the product in Germany in December 2025 [12] - The company signed a strategic collaboration with Immutep to develop and commercialize the investigational immuno-oncology therapy eftilagimod alfa (efti) outside major markets, involving a $20 million upfront payment and potential milestone payments of up to $349.5 million [17][18]

Core Insights - Immutep Limited has received a cash payment of €2,588,954 (~ A$4,567,769) from the French Government under the Crédit d'Impôt Recherche (CIR) scheme, which supports R&D activities [1][3] - The CIR allows French companies to be reimbursed 30% of their eligible R&D expenditures, benefiting Immutep through its subsidiary in France [2][3] - The funds will be allocated to the global clinical development of Immutep's products, specifically eftilagimod alfa and IMP761 [4] Company Overview - Immutep is a late-stage biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases, particularly leveraging LAG-3 therapeutics [5] - The company aims to provide innovative treatment options and maximize shareholder value through its diversified product portfolio [5]

Core Insights - Immutep Limited has received positive feedback from the FDA regarding the clinical development of its MHC Class II agonist, eftilagimod alfa (efti), for first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) patients with PD-L1 expression below 1 [1][2][4] Clinical Development - The FDA acknowledged the potential of efti in combination with Merck's KEYTRUDA (pembrolizumab) for patients with CPS <1, indicating support for further development of this combination therapy [2][4] - Future clinical development paths may include a randomized registrational trial comparing efti with KEYTRUDA against standard-of-care therapy or a smaller single-arm study focusing on safety and response rates, followed by a confirmatory randomized study [3][6] Market Need - Patients with CPS <1 in 1L HNSCC represent a significant unmet medical need, with up to 20% of these patients not benefiting from current anti-PD-1 therapies, which are only approved for those with PD-L1 expression (CPS >1) [7] - Current treatment options for patients with PD-L1 CPS <1 are limited to chemotherapy [7] Company Focus - The primary focus of Immutep remains on the pivotal TACTI-004 Phase III trial evaluating efti as first-line therapy for non-small cell lung cancer, with positive feedback from physicians regarding its progress [5] - The company is considering future collaborative clinical development paths for head and neck cancer based on FDA feedback [4][5] About Immutep - Immutep is a late-stage biotechnology company specializing in immunotherapies for cancer and autoimmune diseases, particularly focusing on Lymphocyte Activation Gene-3 (LAG-3) [8] - The company aims to leverage its expertise to provide innovative treatment options and maximize shareholder value [8]

Core Insights - Immutep Limited has successfully dosed the first patient in its pivotal TACTI-004 Phase III trial, evaluating eftilagimod alfa in combination with KEYTRUDA and chemotherapy for advanced non-small cell lung cancer [1][6] Company Overview - Immutep is a late-stage biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases, particularly leveraging LAG-3 to stimulate or suppress immune responses [8] Trial Details - TACTI-004 is a randomized, double-blind, controlled Phase III study enrolling approximately 756 patients across over 150 clinical sites in more than 25 countries, targeting advanced or metastatic non-small cell lung cancer without specific genomic aberrations [5][7] - The trial's dual primary endpoints are progression-free survival and overall survival, with recruitment currently underway [7] Market Context - Lung cancer is the leading cause of cancer-related deaths, with an expected increase to approximately 3 million cases globally by 2030, and non-small cell lung cancer (NSCLC) accounts for about 80-85% of all lung cancer diagnoses [3] - There is a significant unmet need for new treatment options in NSCLC, as less than 30% of patients survive five years post-diagnosis [3]